This case report documents a reactivation of a pulmonary pathology, beginning some hours after the administration of a first dose of BNT162b2 mRNA vaccine, in a patient having presented a symptomatic pulmonary form of covid-19 one month before. The lessons to be learned and the possible involved mechanisms are discussed.